Filter Results:
- Full text PDF available (7)
Publication Year
1999
2018
- This year (4)
- Last 5 years (16)
- Last 10 years (27)
Publication Type
Co-author
Journals and Conferences
Learn More
Measuring respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diary
- Nancy Kline Leidy, Carlton C. Sexton, +6 authors Sanjay Sethi
- Thorax
- 2014
BACKGROUND
Although respiratory symptoms are characteristic features of COPD, there is no standardised method for quantifying their severity in stable disease.
OBJECTIVE
To evaluate the… (More)
- Geoffrey L. Chupp, Eric Bradford, +6 authors Anneke ten Brinke
- The Lancet. Respiratory medicine
- 2017
BACKGROUND
Mepolizumab, an anti-interleukin-5 monoclonal antibody approved as add-on therapy to standard of care for patients with severe eosinophilic asthma, has been shown in previous studies to… (More)
- Felicia C. Allen-Ramey, Phong T Duong, +4 authors Leona E. Markson
- Allergy and asthma proceedings
- 2003
We compared measures of treatment effectiveness when inhaled corticosteroids (ICSs) or leukotriene modifiers (LMs) were used as controller monotherapy for asthma. Asthma patients aged 6-55 years… (More)
- Erkka Juhani Valovirta, MarÃa Lina Boza, +7 authors Deborah M Gurner
- Annals of allergy, asthma & immunology : official…
- 2011
BACKGROUND
No standard, optimal treatment exists for severe intermittent (ie, episodic) asthma in children. However, evidence suggests that both daily and episode-driven montelukast are effective for… (More)
- Steven Greenberg, Nancy Y. N. Liu, +7 authors Barbara A Knorr
- Respiratory medicine
- 2012
Classifying disease activity in asthma relies on clinical and physiological variables, but these variables do not capture all aspects of asthma that distinguish levels of disease activity. We used… (More)
- Frank C. Albers, Hanna Müllerova, +5 authors Robert Y. Suruki
- The Journal of asthma : official journal of the…
- 2018
OBJECTIVES
Severe asthma comprises several distinct phenotypes. Consequently, patients with severe asthma can be eligible for more than one biologic treatment targeting Th2 inflammation, such as… (More)
- Linda M. Nelsen, Kristine E Shields, +6 authors George Philip
- The Journal of allergy and clinical immunology
- 2012
0 5 min Epinephrine 1:1000, 0.3 mL SQ PF 420 Loratadine, 10 mg po 10 min Prednisone, 50 mg po BP 102/50, HR 88, RR 18 15 min BP 102/60 17 min Epinephrine 1:1000, 0.3 mL SQ Loratadine, 10 mg PF 420 25… (More)
- Craig A. Jones, Nancy C. Santanello, Stephen J. Boccuzzi, J. A. Cima andW. R. Wogen, Peg Strub, Linda M. Nelsen
- The Journal of asthma : official journal of the…
- 2003
BACKGROUND
Failure to use asthma controller medications as prescribed is associated with more asthma-related adverse events. Medication utilization may vary with ease of drug administration,… (More)
- Daisy S Ng-Mak, Kristina Fitzgerald, +6 authors Marcelo Eduardo Bigal
- Headache
- 2011
OBJECTIVE
To understand migraine postdrome by directly interviewing migraine patients with postdrome symptoms. To document these symptoms, as well as impacts, as a prelude to developing a postdrome… (More)
- Nancy C. Santanello, Josephine Norquist, Linda M. Nelsen, Valerie Williams, Cheryl D. Hill, Hans Bisgaard
- Pediatric pulmonology
- 2005
Acute respiratory syncytial virus (RSV)-induced bronchiolitis is often associated with continuing respiratory symptoms following hospitalization. To date, there is no validated objective measure to… (More)